Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Targeting Peptide Mimics Fibronectin

Technology #z06074

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Collections
Image Gallery
Targeting Peptide Mimics FibronectinTissue EngineeringExtracellular Matrix
Categories
Researchers
Efrosini Kokkoli, PhD
Assistant Professor, Chemical Engineering and Material Science, College of Science and Engineering
External Link (www.cems.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

COMPOUNDS THAT BIND ALPHA5BETA1 INTEGRIN AND METHODS OF USE

US Patent 8343539

Fibronectin-Mimicking Targeting Peptide Binds Alpha-5 Beta-1 Integrin

A targeting peptide that mimics the fibronectin protein and binds to alpha-5 beta-1 integrin cell surface receptors has fewer toxic side effects and increases drug efficacy. This peptide has applications in both tissue engineering and targeted drug delivery. Alpha-5 beta-1 anchors cells to the extracellular matrix and plays an important role in angiogenesis. This peptide has been shown to outperform fibronectin during in vitro cell studies. It binds with alpha-5 beta-1 integrins with such great affinity that it promotes extracellular matrix protein production to the same degree as fibronectin. Therefore, this peptide can be used in the place of fibronectin in tissue engineering applications. This peptide also has applications for targeted drug delivery. Many disease states, including cancer, have characteristic changes in alpha-5 beta-1 integrin expression. The binding properties of this peptide indicate that it could have utility for drug delivery in these disease states. This peptide is particularly attractive for targeting therapeutics to colon and prostate cancer cells, which are upregulated in alpha-5 beta-1 integrins.

MN-IP Try and Buy
Try
  • Trial period: 12 to 18 months. $5000/6 months.
  • Fee waived if MN-based company or if sponsoring $50,000+ in research.
Buy
  • Exclusive license for a $35,000 conversion payment
  • No patent costs due
  • 3% royalty after $1 million of product sales
  • Discount for MN companies

** View the Term Sheet **

** Contact Rebecca Gerber for specific details. **


BENEFITS OF TARGETING PEPTIDE FOR TARGETED DRUG DELIVERY AND TISSUE ENGINEERING:

  • Improved targeting would reduce toxic side effects caused by non-specific chemotherapeutic delivery and would increase drug efficacy by targeting correct cells in the extracellular matrix
  • Outperforms fibronectin during in vitro cell studies showing utility as a fibronectin substitute in tissue engineering applications and for integrin targeting when fibronectin is ineffective
  • First synthesized protein that outperforms the protein that it is mimicking
  • Peptide is resistant to degradation and is easily synthesized
  • Peptide can be implemented into nanovectors or liposomes for drug delivery